The effect of danaparoid sodium (danaparoid) on endotoxin-induced experimental disseminated intravascular coagulation (DIC) in rats

Thrombosis Research

Volumn 91, Issue 5, 1998, Pages 221-227

  Fujishima, Yuko ^a   Yokota, Koichi ^a   Sukamoto, Takayuki ^a  

^a KANEBO LTD   (Japan)

Author keywords

Danaparoid sodium; Disseminated intravascular coagulation; Heparin sodium; Rat

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; DANAPAROID; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; HEPARIN; HEPARIN COFACTOR II;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFECT; FIBRIN DEPOSITION; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; THROMBOCYTE COUNT;

ANIMALS; ANTICOAGULANTS; CHONDROITIN SULFATES; DERMATAN SULFATE; DISSEMINATED INTRAVASCULAR COAGULATION; DRUG COMBINATIONS; ENDOTOXINS; HEPARITIN SULFATE; MALE; RATS; RATS, WISTAR;

EID: 0032167745     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00094-2     Document Type: Article

References (26)

1. Rodger L.B. Disseminated intravascular coagulation and related syndromes. A clinical review Semin Thromb Hemost. 14:1988;299-338.
2. Müller-Berghaus G. Pathophysiologic and biochemical events in disseminated intravascular coagulation. dysregulation of procoagulant and anticoagulant pathways Semin Thromb Hemost. 15:1989;58-87.
3. Merskey C., Johnson A.J., Kleiner G.J., Wohl H. The defibrination syndrome. Clinical features and laboratory diagnosis Br J Haematol. 13:1967;528-549.
4. Thiagarajah S., Wheby M.S., Jain R., May H.V., Bourgeois J., Kitchin J.D. Disseminated intravascular coagulation in pregnancy. The role of heparin therapy. J Reprod Med. 26:1981;17-20.
5. Rosenberg R.D. Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism. Am J Med. 87(Suppl 3B):1989;2S-9S.
6. Klein H.G., Bell W.R. Disseminated intravascular coagulation during heparin therapy. Ann Intern Med. 80:1974;477-481.
7. Marciniak E., Gockerman J.P. Heparin-induced decrease in circulating antithrombin-III. Lancet. 2:1977;581-584.
8. Meuleman D.G. Orgaran (Org 10172). Its pharmacological profile in experimental models Haemostasis. 22:1992;58-65.
9. Turpie A.G.G. Orgaran in the prevention of deep vein thrombosis in stroke patients. Haemostasis. 22:1992;92-98.
10. Hobbelen P.M.J., Vogel G.M.T., Princen A.W.M., Meuleman D.G. Benefit (antithrombotic)/risk (bleeding) ratio of various heparin(oid)s in experimental models in rats. Thromb Haemost. 54:1985;32.
11. Takabuchi H., Tsuji H., Yoneda M., Takada O., Watanabe M., Uno M., Kato K., Yamamoto K., Kobayashi K., Sawada S., Nakagawa M. Anticoagulant profile of low molecular weight heparinoids (KB-101) and its in vivo effects on experimental DIC. Jpn J Thromb Hemost. 3:1992;169-177.
12. Vogel G.M.T., Meuleman D.G., Bourgondiën F.G.M., Hobbelen P.M.J. Comparison of two experimental thrombosis models in rats. Effects of four glycosaminoglycans. Thromb Res. 54:1989;399-410.
13. Abildgaard U., Lie M., Ødegård O.R. Antithrombin (heparin cofactor) assay with "new" chromogenic substrates (S-2238 and chromozym TH). Thromb Res. 11:1977;549-553.
14. Bertina R.M., van der Linden I.K., Engesser L., Muller H.P., Brommer E.J.P. Hereditary heparin cofactor II deficiency and the risk of development of thrombosis. Thromb Haemost. 57:1987;196-200.
15. Morrison D.C., Ulevitch R.J. The effects of bacterial endotoxins on host mediation systems. Am J Pathol. 93:1978;527-618.
16. Miyashima T., Hayashi K., Awai M. Initiation and recovery processes of endotoxin induced disseminated intravascular coagulation (DIC). Scanning and transmission electron microscopic observations of rat renal tissues Acta Med Okayama. 43:1989;115-126.
17. Hobbelen P.M.J., Vogel G.M.T., Meuleman D.G. Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factors Xa and thrombin after administration of low molecular weight heparinoid Org 10172 or heparin to rats. Thromb Res. 48:1987;549-558.
18. Yasunaga K., Ogawa N., Mori K., Aoki N., Matsuda T., Nakagawa M., Kakishita E., Kuramoto J., Maruyama M. Evaluation of clinical effect of danaparoid sodium (KB-101) on disseminated intravascular coagulation (DIC). Double blind comparative study Jpn Pharmacol Ther. 23:1995;2815-2834.
19. Pizzo S.V. Serpine receptor 1. A hepatic receptor that mediates the clearance of antithrombin III-proteinase complexes Am J Med. 87(Suppl 3B):1989;10S-14S.
20. Pratt C.W., Church F.C., Pizzo S.V. In vivo catabolism of heparin cofactor II and its complex with thrombin. evidence for a common receptor-mediated clearance pathway for three serine proteinase inhibitors Arch Biochem Biophys. 262:1988;111-117.
21. Fernandez F.A., Buchanan M.R., Hirsh J., Fenton J.W. II, Ofosu F.A. Catalysis of thrombin inhibition provides an index for estimating the antithrombotic potential of glycosaminoglycans in rabbits. Thromb Haemost. 57:1987;286-293.
22. Suchman A.L., Griner P.F. Diagnostic uses of the activated partial thromboplastin time and prothrombin time. Ann Intern Med. 104:1986;810-816.
23. Petitti D.B., Strom B.L., Melmon K.L. Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J Clin Epidemiol. 42:1989;759-764.
24. Carter C.J., Kelton J.G., Hirsh J., Cerskus A., Santos A.V., Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood. 59:1982;1239-1245.
25. Bergstein J.M., Hoyer J.R., Michael A.F. Glomerular fibrinolytic activity following endotoxin-induced glomerular fibrin deposition in the pregnant rat. Am J Pathol. 75:1974;195-202.
26. Andrade-Gordon P., Strickland S. Interaction of heparin with plasminogen activators and plasminogen. effects on the activation of plasminogen Biochemistry. 25:1986;4033-4040.